Understanding Vabysmo for Retinal Disease
How Vabysmo Works
Vabysmo works differently from most other retinal injection medications. Understanding its mechanism helps explain why it may offer longer-lasting results for some patients.
Most injectable retina medications target a single protein called VEGF-A, which triggers abnormal blood vessel growth and fluid leakage in the retina. Vabysmo is a bispecific antibody, meaning it is designed to block two proteins at the same time: VEGF-A and angiopoietin-2, also called Ang-2.
Ang-2 is a protein that destabilizes blood vessels, making them leaky and fragile. When both Ang-2 and VEGF-A are elevated, fluid leaks into the retina more aggressively. By blocking both proteins simultaneously, Vabysmo helps stabilize blood vessels more completely than medications that target VEGF-A alone.
This dual mechanism is believed to be why many patients experience more durable retinal drying and can go longer between treatments.
Vabysmo is delivered as an intravitreal injection, meaning it is injected directly into the vitreous, the clear gel that fills the inside of the eye. Numbing drops and an antiseptic rinse are applied to the eye before the injection. The injection itself takes only a few seconds, and the full appointment typically lasts between 15 and 30 minutes.
Conditions Vabysmo Treats
Vabysmo has received FDA approval for three retinal conditions. Each of these conditions causes fluid buildup or abnormal blood vessel activity in the retina that, without treatment, can lead to permanent vision loss.
In wet AMD, abnormal blood vessels grow beneath the retina and leak fluid or blood. This damages the macula, the central portion of the retina responsible for sharp detail vision used in reading, driving, and recognizing faces. Vabysmo helps reduce this leakage and slow vision loss. When treatment begins early, some patients also experience meaningful vision improvement.
Diabetic macular edema, or DME, occurs when diabetes causes fluid to accumulate in the macula, leading to blurred central vision. DME can develop at any stage of diabetic retinopathy and is one of the most common causes of vision loss in people with diabetes. Vabysmo reduces this fluid buildup and can improve visual clarity over time. Consistent blood sugar management alongside injection treatment supports the best possible outcomes.
Retinal vein occlusion, or RVO, happens when a vein carrying blood away from the retina becomes blocked, causing swelling and fluid leakage in the macula. The FDA approved Vabysmo for this condition in 2023. Vabysmo helps reduce the resulting macular edema and protect vision.
What the Clinical Evidence Shows
Vabysmo was studied in large clinical trials before FDA approval, and real-world evidence has continued to build since then. The results across these studies help explain why this medication has become an important treatment option for retinal disease.
Two large trials, TENAYA and LUCERNE, compared Vabysmo to Eylea (aflibercept) in patients with wet AMD, enrolling more than 1,300 patients combined. Results showed that Vabysmo was comparable to Eylea for improving vision. Importantly, nearly 80 percent of wet AMD patients treated with Vabysmo were able to go at least three months between injections after the initial loading phase, and approximately 60 percent extended to four-month intervals.
For DME, the YOSEMITE and RHINE trials enrolled more than 1,800 patients. Those treated with Vabysmo gained an average of 11 letters on an eye chart over one year, a result similar to Eylea. Fluid clearance from the retina was also notably strong, with a higher proportion of Vabysmo-treated patients showing no retinal fluid at 12 weeks compared to those treated with aflibercept. These findings suggest Vabysmo may offer a more complete drying effect in some patients.
Since Vabysmo became available, a substantial body of real-world evidence has confirmed that trial results translate well to everyday clinical practice. Studies show that many patients maintain their vision gains while receiving fewer injections per year than they would with older anti-VEGF medications.
Treatment Schedule and What to Expect
Vabysmo treatment follows a structured schedule designed to stabilize the retina quickly and then find the longest safe interval between injections. Your retina specialist will guide each step of this process.
Treatment begins with a loading phase of four monthly injections. These initial doses help build up the medication in the eye and begin reducing fluid and stabilizing the retina. During this period, patients visit their retina specialist approximately once every four weeks.
After the loading phase, many patients can gradually extend the time between treatments. Your retina specialist uses imaging called OCT (optical coherence tomography), a painless scan of the retina, along with vision checks to determine the right interval for your eye. Some patients are able to reach intervals as long as 16 weeks between injections. This personalized approach, sometimes called treat-and-extend, adjusts the schedule based on how each patient responds.
Plan to spend about one to two hours at the office for each injection visit. Most of this time involves check-in, dilating and numbing eye drops, and a brief monitoring period after the injection. The injection itself takes only seconds. You may experience mildly blurred vision for several hours afterward, so arranging for someone to drive you home is a good idea. Most patients return to normal activities the following day.
Who May Benefit from Vabysmo
Vabysmo is not right for every patient, but there are several situations where it may be an especially good fit. Your retina specialist will consider your diagnosis, treatment history, and how your eye responds when recommending a treatment plan.
Patients who have not yet received any anti-VEGF injections may be strong candidates for Vabysmo. Clinical trials included a large proportion of treatment-naive patients, meaning those who had never received injections before, and this group showed strong visual acuity gains. Starting with Vabysmo may allow patients to benefit from extended dosing intervals from the very beginning of treatment.
Frequent injection appointments can be a significant burden, requiring travel, time away from work or family, and the ongoing stress of the procedure itself. For patients whose eyes respond well to Vabysmo, fewer annual visits may be possible compared to some older medications. This can be especially meaningful for patients who depend on others for transportation or who live at a distance from a retina specialist's office.
Some patients already receiving anti-VEGF injections with another medication may consider switching to Vabysmo. Common reasons include persistent fluid visible on retinal imaging despite regular injections, or a desire for longer intervals between treatments. Your retina specialist can evaluate your imaging history and discuss whether switching may offer a benefit for your specific situation.
Preparing for Your Appointments
Knowing what to expect before and during treatment helps reduce anxiety and supports the best possible outcomes. A little preparation goes a long way toward making each visit as smooth as possible.
Your retina specialist will perform a comprehensive eye examination before starting Vabysmo. This typically includes a dilated exam, OCT imaging, and possibly fluorescein angiography, a test that uses a special dye injected into the arm to photograph blood flow in the retina. These tests confirm the diagnosis and create a baseline for tracking how your eye responds to treatment. Bring a complete list of all medications you take, including any blood thinners.
Because your eyes will be dilated for imaging and monitoring, bright light may be uncomfortable for a few hours after your visit. Wearing sunglasses and arranging for a ride home is strongly recommended. You do not need to skip meals or follow special dietary instructions before an injection appointment.
Even as injection intervals are extended, regular monitoring remains essential. Your retina specialist will check your vision and perform OCT scans at every visit to evaluate whether fluid remains in the retina. These results guide decisions about whether to maintain, extend, or shorten the interval between injections. Keeping all scheduled appointments is one of the most important things you can do to protect your vision over the long term.
How Vabysmo Compares to Other Treatments
Several effective anti-VEGF medications are available for retinal disease. Understanding how Vabysmo differs from other options helps patients have more informed conversations with their retina specialist.
Eylea (aflibercept) and Lucentis (ranibizumab) are well-established medications that target VEGF-A only. They have long safety records built over more than a decade of clinical use and require injections every four to eight weeks in most cases. Vabysmo's dual-target mechanism allows many patients to extend treatment intervals further while achieving comparable vision outcomes. The best choice between these options depends on your individual condition, treatment history, and response.
Avastin (bevacizumab) is used off-label for retinal conditions, meaning it was originally FDA-approved for a different purpose (cancer treatment) but has been studied extensively for eye disease. It has been shown to be effective and costs significantly less than other anti-VEGF options. However, it typically requires more frequent dosing than newer agents like Vabysmo. For patients where reducing the number of annual injections is a priority, Vabysmo's extended intervals may be an important factor in the decision.
Each anti-VEGF medication has its own profile of benefits, and patient responses vary. Your retina specialist will consider your specific diagnosis, the severity of your condition, your treatment history, and your preferences when recommending an approach. Switching between medications is common if the initial treatment does not achieve the desired result.
Safety and Side Effects
Like all intravitreal injections, Vabysmo carries a small risk of side effects. Most are mild and resolve on their own, but it is important to know which symptoms require prompt attention.
The most commonly reported side effects in clinical trials included cataract development and conjunctival hemorrhage, a small area of bleeding on the white of the eye that looks alarming but is usually harmless and clears on its own within one to two weeks. These effects were generally mild and occurred at rates similar to those seen with other anti-VEGF medications. Brief redness, mild irritation, or a sensation of grittiness in the eye after an injection are also common and typically resolve within a day or two.
Serious complications from intravitreal injections are uncommon but can occur. These include endophthalmitis (infection inside the eye), a significant increase in eye pressure, retinal detachment, and vitreous hemorrhage (bleeding inside the eye). Retinal vasculitis, meaning inflammation of the blood vessels in the retina, has been reported rarely with Vabysmo. Your retina specialist takes careful precautions during every injection to minimize these risks.
Reach out to your retina specialist right away, or go to an emergency room, if you experience sudden vision loss, increasing eye pain, worsening redness, or a notable increase in floaters after an injection. These symptoms can signal a serious complication that requires prompt evaluation and treatment. Do not wait to see if the symptoms improve on their own.
Frequently Asked Questions
These answers address common questions patients have when considering or starting Vabysmo treatment.
The answer depends largely on your diagnosis. Wet AMD typically requires ongoing treatment because the underlying disease is chronic, though the goal over time is to find the longest safe interval between injections. In some DME cases, treatment may eventually be paused if the condition fully stabilizes, but this decision is always made carefully with ongoing monitoring. Your retina specialist will reassess your plan at each visit based on your imaging and vision results.
Most patients find the injection more manageable than they expected. The eye is thoroughly numbed with anesthetic drops before the procedure, so the sensation is usually one of mild pressure rather than sharp pain. Any discomfort tends to pass quickly. If you experience more than very mild soreness in the hours after an injection, let your retina specialist know at your next visit.
Vabysmo can improve vision for many patients, especially when treatment begins before significant retinal damage has occurred. That said, results vary depending on the extent and duration of disease. Some patients see meaningful visual improvement, while others experience stabilization that prevents further loss. Vision lost due to longstanding or severe retinal damage may not be fully recoverable, which is one reason early treatment is so important.
It is not uncommon for patients to experience changes in their response to a medication over months or years. If your retina specialist sees persistent or recurring fluid on OCT imaging despite regular Vabysmo treatments, a switch to a different anti-VEGF medication may be recommended. Adjusting the dosing interval is another option before considering a switch. Open communication with your care team about any changes in your vision between appointments is always helpful.
Vabysmo is FDA-approved and covered by most major insurance plans, including Medicare, for its approved indications. Coverage details, including co-pays and prior authorization requirements, vary by plan. Our team can help you understand your benefits and navigate the authorization process before your first injection.
On the day of your injection, it is best to avoid rubbing your eye, swimming, or using eye makeup. Most patients can resume normal activities the following day. Your retina specialist may provide specific post-injection instructions, and it is important to follow those guidelines carefully to support healing and reduce infection risk.
Expert Retina Care at Rhode Island Eye Institute
Our retina specialists, Dr. Gaurav Gupta and Dr. Pranjal Thakuria, bring fellowship-trained expertise and a patient-centered approach to every evaluation and treatment. At Rhode Island Eye Institute, we are committed to helping patients with retinal disease understand their options, protect their vision, and receive the most current, evidence-based care available. We welcome you to schedule a consultation and take the next step toward preserving your sight.